Search research articles
Contact Us
Filters
Showing results (21-30 of 107) with videos related to
Page
of 11
Sort By:
Annales De Biologie Clinique
|
June 16, 2018
[Chronic lymphocytic leukemia with t(14 ;18) and trisomy 12: a case report]
Maïlys Le Guyader, Marie Coude, Kamel Laribi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 30, 2015
Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France
Alain Toledano, Elisabeth Luporsi, Jean François Morere, et al.
Annales De Biologie Clinique
|
August 7, 2018
[Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis]
Jérôme Debus, Pierre Lemaire, Mustafa Alani, et al.
Hematological Oncology
|
April 6, 2022
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Julien Labreuche, Deborah Assouan, Eric Durot, et al.
Clinical Pharmacokinetics
|
October 27, 2016
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group
Mira Tout, Anne-Laure Gagez, Stéphane Leprêtre, et al.
The Lancet. Oncology
|
February 13, 2018
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, et al.
Hematological Oncology
|
July 23, 2016
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma
Kamel Laribi, Adrien Tempescul, Habib Ghnaya, et al.
Annals of Hematology
|
August 10, 2018
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma
Jonathan Farhi, Kamel Laribi, Corentin Orvain, et al.
Annals of Hematology
|
July 30, 2025
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)
Anne Quinquenel, Stéphane Leprêtre, Marie Sarah Dilhuydy, et al.
British Journal of Haematology
|
March 20, 2024
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
Kamel Laribi, Stéphanie Poulain, Lise Willems, et al.
Page
of 11
Search research articles
Search
Showing results (21-30 of 107) with videos related to
Sort By:
Page
of 11
Annales De Biologie Clinique
|
June 16, 2018
[Chronic lymphocytic leukemia with t(14 ;18) and trisomy 12: a case report]
Maïlys Le Guyader, Marie Coude, Kamel Laribi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 30, 2015
Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France
Alain Toledano, Elisabeth Luporsi, Jean François Morere, et al.
Annales De Biologie Clinique
|
August 7, 2018
[Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis]
Jérôme Debus, Pierre Lemaire, Mustafa Alani, et al.
Hematological Oncology
|
April 6, 2022
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Julien Labreuche, Deborah Assouan, Eric Durot, et al.
Clinical Pharmacokinetics
|
October 27, 2016
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group
Mira Tout, Anne-Laure Gagez, Stéphane Leprêtre, et al.
The Lancet. Oncology
|
February 13, 2018
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, et al.
Hematological Oncology
|
July 23, 2016
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma
Kamel Laribi, Adrien Tempescul, Habib Ghnaya, et al.
Annals of Hematology
|
August 10, 2018
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma
Jonathan Farhi, Kamel Laribi, Corentin Orvain, et al.
Annals of Hematology
|
July 30, 2025
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)
Anne Quinquenel, Stéphane Leprêtre, Marie Sarah Dilhuydy, et al.
British Journal of Haematology
|
March 20, 2024
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
Kamel Laribi, Stéphanie Poulain, Lise Willems, et al.
Page
of 11